See Supplemental Patient Information
- Use sodium iodide I-131 for the treatment of hyperthyroidism in patients <30 years of age only if circumstances preclude other methods of treatment
- Prior to therapy administration, the patient should be questioned carefully regarding previous medication and procedures involving radiographic contrast media
- Therapy may cause radiation thyroiditis, which may worsen hyperthyroidism and thyrotoxic cardiac disease. Consider pre–treatment and post-treatment with antithyroid medications and/or beta-blockers, such as propranolol
- Low serum chlorides or nephrosis may increase thyroid uptake of sodium iodide I-131
- Enhanced TSH secretion following discontinuation of antithyroid agents or the administration of TSH to enhance sodium iodide I-131 uptake may cause thyroid enlargement and obstructive complications of the trachea, esophagus, or blood vessels in the neck
- Renal impairment may decrease excretion of radioiodide and increase the amount of radiation exposure
- Therapy should be administered by nuclear physicians and/or radiopharmacists well trained and experienced in the safe use and handling of radionuclides
- Radiation-induced toxicities, e.g., salivary and lacrimal gland toxicity, including dose-dependent fatalities, have been reported following therapy administration
- Transplacental passage of the agent may cause severe and possibly irreversible hypothyroidism in neonates
- Care should be taken to minimize radiation exposure to the patient consistent with proper patient management and to assure minimum exposure to occupational workers
- Transient, dose-related impairment of testicular function has been associated with the therapy; consider sperm banking for men who are anticipated to receive a high cumulative dose of sodium iodide I-131
- Sodium iodide I-131 solution contains a sulfite (sodium bisulfite) that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people
Caution: Use cautiously in
Supplemental Patient Information
- Instruct patients to inform their physicians if they are allergic to any drugs or food, or if they have any immune/autoimmune/immune deficiency disorders. Also, instruct them to inform if they had any reactions to previous injections of dyes used for x-ray procedures
- Discuss the measures to minimize the radiation contamination of the patient, members of the patient's household, and the environment
- Advise patients of reproductive potential of the need to use two effective methods of contraception to avoid pregnancy for at least 6 months to 1 year after therapy due to fetal risk
- Instruct lactating females to discontinue breastfeeding and pumping at least 4 wks before therapy administration. Advise nursing mothers not to breastfeed their infants if sodium iodide I-131 is administered in the postpartum period
Pregnancy Category:X
Breastfeeding: Elective diagnostic nuclear medicine procedures should be delayed until the patient is no longer breastfeeding. Alternate agents are preferred. Breastfeeding should be discontinued permanently for this child after administration of sodium iodide I 131 in a dose of 0.01 MBq (0.004 mCi) or greater to a nursing mother. Cease breastfeeding 6 weeks to 3 months before receiving a therapeutic dose. This information is based upon LactMed database http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 1 August 2011). Sodium iodide I-131 is excreted in breast milk and may reach concentrations equal to or greater than concentrations in maternal plasma. According to manufacturer's data, formula feeding should be substituted for breast feeding until radiation levels have substantially decreased.
US Trade Name(s)
US Availability
sodium iodide I-131 (generic)
- CAPS: 0.75-100 mCi
- SOLN: 5-150 mCi/vial
Hicon
- SOLN: 250 mCi/vial (1 mL vial)
- SOLN: 500 mCi/vial (1 mL vial)
- SOLN: 1000 mCi/vial (1 mL vial)
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
sodium iodide I-131 (generic)
- SOLN: 50-6000 MBq/vial
- CAPS: 50-6000 MBq
[Outline]
